[go: up one dir, main page]

MX2022009628A - Métodos para el tratamiento de la esclerodermia y padecimientos relacionados. - Google Patents

Métodos para el tratamiento de la esclerodermia y padecimientos relacionados.

Info

Publication number
MX2022009628A
MX2022009628A MX2022009628A MX2022009628A MX2022009628A MX 2022009628 A MX2022009628 A MX 2022009628A MX 2022009628 A MX2022009628 A MX 2022009628A MX 2022009628 A MX2022009628 A MX 2022009628A MX 2022009628 A MX2022009628 A MX 2022009628A
Authority
MX
Mexico
Prior art keywords
scleroderma
treatment
methods
related conditions
igf
Prior art date
Application number
MX2022009628A
Other languages
English (en)
Inventor
Elizabeth Thompson
Srini Ramanathan
Original Assignee
Horizon Therapeutics Ireland Dac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Dac filed Critical Horizon Therapeutics Ireland Dac
Publication of MX2022009628A publication Critical patent/MX2022009628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan anticuerpos contra el receptor del factor de crecimiento similar a la insulina 1 (IGF-1R) y su uso en métodos de tratamiento y en la obtención de resultados clínicos en la esclerodermia y formas de esta, incluida la esclerosis sistémica cutánea difusa.
MX2022009628A 2020-02-04 2021-02-04 Métodos para el tratamiento de la esclerodermia y padecimientos relacionados. MX2022009628A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970063P 2020-02-04 2020-02-04
US202063049522P 2020-07-08 2020-07-08
PCT/US2021/016666 WO2021158823A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Publications (1)

Publication Number Publication Date
MX2022009628A true MX2022009628A (es) 2022-11-07

Family

ID=77200418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009628A MX2022009628A (es) 2020-02-04 2021-02-04 Métodos para el tratamiento de la esclerodermia y padecimientos relacionados.

Country Status (11)

Country Link
US (2) US20210253686A1 (es)
EP (1) EP4100127A4 (es)
JP (1) JP2023515771A (es)
KR (1) KR20220151619A (es)
CN (1) CN115397518A (es)
AU (1) AU2021217378A1 (es)
BR (1) BR112022015447A2 (es)
CA (1) CA3169994A1 (es)
IL (1) IL295372A (es)
MX (1) MX2022009628A (es)
WO (1) WO2021158823A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250367267A1 (en) * 2022-06-29 2025-12-04 Lirum Therapeutics, Inc. Treating autoimmune diseases with insulin-like growth factor 1 receptor ligand conjugated to an agent
WO2025007012A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for rheumatoid arthritis
WO2025007015A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis
CN119548621A (zh) * 2023-09-01 2025-03-04 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833559A1 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
CA2855566A1 (en) * 2011-12-02 2013-06-06 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
EP2647994A1 (en) * 2012-04-03 2013-10-09 Universitätsklinikum Freiburg Method for diagnosis of pulmonary involvement in systemic sclerosis
CN107982247A (zh) * 2018-01-23 2018-05-04 中日友好医院 二甲双胍在制备治疗肺纤维化药物中的应用
WO2019161000A1 (en) * 2018-02-15 2019-08-22 Children's Hospital Medical Center Methods for treating fibrosis

Also Published As

Publication number Publication date
AU2021217378A1 (en) 2022-09-01
BR112022015447A2 (pt) 2022-11-16
IL295372A (en) 2022-10-01
KR20220151619A (ko) 2022-11-15
EP4100127A4 (en) 2024-02-28
JP2023515771A (ja) 2023-04-14
US20210253686A1 (en) 2021-08-19
US20240279323A1 (en) 2024-08-22
CA3169994A1 (en) 2021-08-12
EP4100127A1 (en) 2022-12-14
CN115397518A (zh) 2022-11-25
WO2021158823A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MX2022009628A (es) Métodos para el tratamiento de la esclerodermia y padecimientos relacionados.
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
AU2018263862A1 (en) Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
TNSN05300A1 (en) Treatment with anti-vegf antibodies
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
SV2006002182A (es) Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip
EP4219556A3 (en) Human monoclonal antibodies specific for flt3 and uses thereof
PH12020551057A1 (en) Group b adenovirus-containing formulation
WO2021263227A3 (en) Anti-nme antibody and method of treating cancer or cancer metastasis
EP4582446A3 (en) Methods of treating al amyloidosis
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
EP2431050A8 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2021015336A (es) Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide.
WO2020005934A8 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
AR043252A1 (es) Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica
MY210310A (en) Methods for treatment of subjects with psoriatic arthritis